| 1 |
Guideline 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. free! 2007
Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E, Anonymous00134. · Department of Medicine, Julia McFarlane Diabetes Research Centre, Diabetes and Endocrine Research Group, University of Calgary, Calgary, Alta. · CMAJ. · Pubmed #17420481 links to free full text
This publication has no abstract.
|
| 2 |
Clinical Conference Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. free! 1999
Barak Y, Ur E, Achiron A. · Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel. · J Neuropsychiatry Clin Neurosci. · Pubmed #10334000 links to free full text
Abstract: Depression is common in multiple sclerosis (MS) patients, but tricyclic compounds are not well tolerated and newer antidepressants have not been studied. Effects of 150-400 mg/day of moclobemide, a reversible monoamine oxidase A inhibitor, were studied in a 3-month open design in 10 MS patient with DSM-IV-diagnosed depression. Nine patients reached complete remission. No adverse effects were noted. Four patients reported side effects including nausea and insomnia. The authors conclude that moclobemide is a well tolerated and efficient treatment for depression comorbid with MS.
|